Association between subclinical thyroid dysfunction and change in bone mineral density in prospective cohorts

Authors:

Abstract
Background: Subclinical hyperthyroidism (SHyper) has been associated with increased risk of hip and other fractures, but the linking mechanisms remain unclear.Objective: To investigate the association between subclinical thyroid dysfunction and bone loss.Methods: Individual participant data analysis was performed after a systematic literature search inMEDLINE/EMBASE(1946–2016). Two reviewers independently screened and selected prospective cohorts providing baseline thyroid status and serial bone mineral density (BMD) measurements. We classified thyroid status as euthyroidism (thyroid‐stimulating hormone [TSH] 0.45–4.49 mIU/L),SHyper (TSH< 0.45 mIU/L) and subclinical hypothyroidism (SHypo, TSH ≥ 4.50–19.99 mIU/L) both with normal free thyroxine levels. Our primary outcome was annualized percentageBMDchange (%ΔBMD) from serial dual X‐ray absorptiometry scans of the femoral neck, total hip and lumbar spine, obtained from multivariable regression in a random‐effects two‐step approach.Results: Amongst 5458 individuals (median age 72 years, 49.1% women) from six prospective cohorts, 451 (8.3%) hadSHypo and 284 (5.2%) hadSHyper. During 36 569 person‐years of follow‐up, those withSHyper had a greater annual bone loss at the femoral neck versus euthyroidism: %ΔBMD= −0.18 (95% CI: −0.34, −0.02;I2= 0%), with a nonstatistically significant pattern at the total hip: %ΔBMD = −0.14 (95% CI: −0.38, 0.10;I2= 53%), but not at the lumbar spine: %ΔBMD = 0.03 (95% CI: −0.30, 0.36;I2= 25%); especially participants with TSH < 0.10 mIU/L showed an increased bone loss in the femoral neck (%Δ BMD = −0.59; [95% CI: −0.99, −0.19]) and total hip region (%ΔBMD = −0.46 [95% CI: −1.05, −0.13]). In contrast,SHypo was not associated with bone loss at any site.Conclusion: Amongst adults,SHyper was associated with increased femoral neck bone loss, potentially contributing to the increased fracture risk.
Funding Information
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNSF 320030‐150025, 320030‐172676, P3SMP3‐155318, PZ00P3‐167826)
  • National Heart, Lung, and Blood Institute (HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, U01HL080295)
  • National Institute of Neurological Disorders and Stroke
  • National Institute on Aging (R01AG023629, N01‐AG‐6‐2101, N01‐AG‐6‐2103, N01‐AG‐6‐2106, R01‐AG028050)
  • National Institute of Nursing Research (R01‐NR012459)
  • National Institutes of Health
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • National Center for Advancing Translational Sciences
  • Sanofi-Aventis Korea Company
  • Eli Lilly and Company
  • Novartis
  • Pfizer
  • Roche
  • Erasmus Medisch Centrum
  • Erasmus Universiteit Rotterdam
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek
  • ZonMw
  • Ministerie van Onderwijs, Cultuur en Wetenschap
  • Ministerie van Volksgezondheid, Welzijn en Sport
  • European Commission
  • European Commission (FP7‐HEALTH‐2011)
  • Arthritis Research UK

This publication has 40 references indexed in Scilit: